Filing Overview
Mangoceuticals, Inc. filed a Form 8-K reporting events occurring on June 3, 2024; the report was signed on June 5, 2024. The filing concerns equity issuances and compensation arrangements, not periodic financial results.
Key Financial and Capitalization Matters
- The filing does not provide revenue, profit, cash flow, margins, debt, cash, liquidity, or other operating financial metrics.
- The Company issued 192,308 restricted common shares to a third-party consultant for professional relations and consulting services under an agreement running through May 23, 2025.
- The consultant agreement also provides for $15,000 in cash compensation per month and additional common-stock compensation valued at $50,000 after the first six months and after the first nine months. The filing text does not clearly state whether the $50,000 amount applies separately to each milestone.
- The Company issued an aggregate of 1,250,000 fully vested and earned common shares under its Amended and Restated 2022 Equity Plan as a 2024 bonus to the CEO and for 2024 services to other recipients.
Equity Awards to Named Officers and Directors
| Recipient | Position | Shares |
|---|---|---|
| Jacob D. Cohen | Chief Executive Officer and Chairman | 800,000 |
| Amanda Hammer | Chief Operating Officer | 100,000 |
| Kenny Myers | Director | 100,000 |
| Alex Hamilton | Director | 100,000 |
| Lorraine D’Alessio | Director | 100,000 |
The named officers and directors received 1,200,000 of the 1,250,000 shares; the filing does not identify the remaining recipient or recipients in the provided text.
Material Changes and Dilution
- The reported issuances totaled at least 1,442,308 common shares, increasing the Company’s outstanding equity and potentially diluting existing shareholders.
- The consultant shares were issued without registration under Section 4(a)(2) and/or Rule 506 of Regulation D and are subject to transfer restrictions.
- The equity-plan shares were issued under registration statements previously filed on Form S-8.
Outlook, Risks, and Unusual Items
- No revenue guidance, earnings outlook, liquidity forecast, or management operating commentary was provided.
- The consultant arrangement creates an ongoing cash obligation of $15,000 per month through the agreement term, in addition to future equity compensation.
- The fully vested equity awards and consultant issuance may increase stock-based compensation expense and shareholder dilution; the filing does not quantify the accounting expense or the resulting ownership percentages.
- The restricted shares may not be resold in the United States absent registration or an applicable exemption.
Investor Verification Items
- Verify the Company’s post-issuance shares outstanding and the percentage dilution from the 1,442,308 shares.
- Confirm the value, timing, and recipients of the additional $50,000 stock payments under the consultant agreement.
- Review the applicable Form S-8 registration statements and equity-plan share availability.
- Assess the accounting impact of the stock awards and the recurring $15,000 monthly consultant payments in subsequent financial statements.
- Confirm the identity of the recipient or recipients of the remaining 50,000 shares from the 1,250,000-share equity award aggregate.